(Q44080548)

29 November 2017

title

Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects (English)

1 reference

29 November 2017

1 reference

3

1 reference

29 November 2017

S Warrington

1

1 reference

29 November 2017

K Baisley

2

1 reference

29 November 2017

B Tejura

4

1 reference

29 November 2017

A Morocutti

5

1 reference

29 November 2017

N Miller

6

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

Alimentary Pharmacology & Therapeutics

29 November 2017

published in

1 reference

29 November 2017

volume

16

1 reference

29 November 2017

issue

7

1 reference

29 November 2017

page(s)

1301-1307

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01292.X

29 November 2017

1 reference

Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01292.X

Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01292.X

Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01292.X

Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01292.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01292.X

Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01292.X

Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01292.X

Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01292.X

Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01292.X

10.1046/J.1365-2036.2002.01292.X

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference